Rocklatan

Phase 3Small molecule

CColorado Ophthalmology Associates PC

Rocklatan is one of 10 small molecule programs targeting Ocular Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionRecruiting

Ocular HypertensionPhase 3

Recruiting

Competition

Competitive Landscape

13 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Zolymbus

AbbVie

Approved

14 2

Travatan

Novartis

Approved

8 3

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

19 4

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—5

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Isopto Carpine

Vyzulta

BBausch Health Americas, Inc.

Approved

1 8

Rocklatan

CColorado Ophthalmology Associates PC

Phase 3

1 9

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Phase 3

1 10

Zioptan

MMeitheal

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Glaucoma

NCT07048886

Q1 2027

ApprovedRecruiting

Ocular Hypertension

NCT04401982

Clinical

Trials by Indication[1]

Treatment1 trial

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment

Completed·CColorado Ophthalmology Associates PC··NCT06819046·70 enrolled

Glaucoma1 trial

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Not yet recruiting·CCenter for Sight Las Vegas·Phase 4·NCT07048886·68 enrolled

Ocular Hypertension1 trial

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Using Erythrocyte Mediated Angiography In Vivo

Recruiting·UUniversity of Maryland, Baltimore·Approved·NCT04401982·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Rocklatan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rocklatan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rocklatan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Colorado Ophthalmology Associates PC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CColorado Ophthalmology Associates PC

Rocklatan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Treatment1 trial

Glaucoma1 trial

Ocular Hypertension1 trial

References

Drug Info

Quick Facts

Related News